Orthobiologics Market to Reach USD 10.4 Billion by 2035

According to analysts at Vantage Market Research, the Global Orthobiologics Market size is worth USD 6.56 Billion in 2024 and is projected to reach USD 10.4 Billion by 2035, growing at a CAGR (Compound Annual Growth Rate) of 5.9% from 2024 to 2035. Key trends of market include rising adoption of minimally invasive techniques, advancements in biomaterials, increasing aging population, and personalized therapies.

Market Overview

The growing preference for minimally invasive surgical procedures is driving demand for orthobiologics attributed to their advantages, including shorter recovery periods, reduced post-operative discomfort, and a lower risk of complications compared to traditional open surgeries. This trend is significantly boosting the adoption of bone grafts and substitutes designed to align with minimally invasive techniques, enhancing procedural efficiency and patient outcomes. These grafts and substitutes need to be easily implantable through small incisions and provide adequate support for bone healing and regeneration in minimally invasive procedures, thus driving innovation and development in the Orthobiologics market.

The global aging population is expanding rapidly, with a substantial proportion of the elderly experiencing musculoskeletal conditions such as osteoarthritis, fractures, and degenerative spine disorders. As individuals age, their bones and joints undergo degenerative changes, leading to an increased need for orthopedic interventions. This demographic shift presents a significant growth opportunity for the market, as older adults increasingly require bone grafts and substitutes to support orthopedic procedures. 

Isto Biologics Launches Influx™ Fibrant, a New Line of Advanced Allograft

• In June 2022, Isto Biologics is a leader in surgical-based, orthobiologic regeneration technologies and cell-based therapies, announced today the launch of Influx™ Fibrant, an unprecedented line of functional constructs derived from 100% cortical allograft. The cutting-edge line consisting of five new products includes Fibrant Anchor, Boat, Bullet, Pak and Wrap

Key Takeaways from the Report

• In 2024, based on the Product type, the Viscosupplementation category accounted for significant market share of 41.80%. Viscosupplementation products are recognized for their strong safety profile, with minimal risk of adverse effects or complications, making them an ideal option for a broad patient demographic.
• Based on the Application, the Spinal Fusion category accounted for significant market share of 52.30% in 2024. Spinal fusion category is driven by the rising prevalence of spinal disorders and advancements in surgical techniques
• In 2024, based on the End Use, the Hospitals category accounted for significant market share of 62.90%. Hospitals play a crucial role in the utilization of orthobiologics due to their advanced medical infrastructure and comprehensive healthcare services
• In 2024, North America dominated the market with 48.30% market share. Market is driven by advancements in regenerative medicine, an increasing prevalence of musculoskeletal disorders

Top Companies

• Medtronic Plc
• DePuy Synthesis
• Zimmer Biomet
• Stryker Corporation
• Anika Therapeutics Inc
• Orthofix Inc
• Bone Biologics Corp.
• Globus Medical
• Bioventus LLC

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision-making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in-depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine regional market landscapes, and evaluate the impact of major events like the COVID-19 pandemic. Additionally, our reports feature a detailed competitive landscape, including company market shares and profiles, providing actionable intelligence to empower your business strategies.

Latest News

Globus Medical completes merger with NuVasive

• In September 2023, Globus Medical Inc. a leading musculoskeletal solution company, announced it has completed its previously announced merger with NuVasive, Inc. The company combined will provide surgeons and patients with one of the most comprehensive offerings of musculoskeletal procedural solutions and enabling technologies to impact the care continumm